Royal Bank of Canada
DNA.WS

Royal Bank of Canada’s Ginkgo Bioworks Holdings, Inc. Warrants, each whole warrant exercisable to purchase one-fortieth (1/40th) of a share of Class A Common Stock at an exercise price of $460.00 per share DNA.WS Stock Holding History

Royal Bank of Canada’s Portfolio DNA.WS Stock Details DNA.WS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-240
Closed – – 7683
2024
Q2 		$0 Sell
240
-560
-70% -$30 ﹤0.01% 7693
2024
Q1 		$0 Hold
800
– – ﹤0.01% 7761
2023
Q4 		$0 Sell
800
-460
-37% -$68 ﹤0.01% 7725
2023
Q3 		$0 Hold
1,260
– – ﹤0.01% 7754
2023
Q2 		$0 Hold
1,260
– – ﹤0.01% 7778
2023
Q1 		$0 Buy
1,260
+600
+91% +$137 ﹤0.01% 7613
2022
Q4 		$0 Hold
660
– – ﹤0.01% 7873
2022
Q3 		$0 Hold
660
– – ﹤0.01% 7999
2022
Q2 		$0 Hold
660
– – ﹤0.01% 7831
2022
Q1 		$1K Hold
660
– – ﹤0.01% 7636
2021
Q4 		$1K Hold
660
– – ﹤0.01% 7561
2021
Q3 		$2K Buy
+660
New +$2.35K ﹤0.01% 7377

Other funds holding DNA.WS

AS
Altshuler Shaham Tel Aviv, Israel $5.54B AUM 44.68% 1-Year Est. Return
SBLIC
Security Benefit Life Insurance Company Topeka, Kansas $182M AUM 31.21% 1-Year Est. Return
HIA
Harbor Investment Advisory Lutherville, Maryland $1.43B AUM 30.71% 1-Year Est. Return
SPIA
Steward Partners Investment Advisory New York $19.6B AUM 22.89% 1-Year Est. Return

Royal Bank of Canada's DNA.WS Position: Q3 2024 in Review

Royal Bank of Canada sold out of Ginkgo Bioworks Holdings, Inc. Warrants, each whole warrant exercisable to purchase one-fortieth (1/40th) of a share of Class A Common Stock at an exercise price of $460.00 per share (DNA.WS) in Q3 2024, closing a stake of 240 shares.

Royal Bank of Canada first reported a position in DNA.WS in Q3 2021 and held it in 12 quarters. The position peaked at $2K in Q3 2021. 5 funds tracked by Wall St. Rank hold DNA.WS as of Q3 2024.

  • Royal Bank of Canada reported no remaining Ginkgo Bioworks Holdings, Inc. Warrants, each whole warrant exercisable to purchase one-fortieth (1/40th) of a share of Class A Common Stock at an exercise price of $460.00 per share position as of Q3 2024 after selling out during the quarter.
  • Royal Bank of Canada sold 240 Ginkgo Bioworks Holdings, Inc. Warrants, each whole warrant exercisable to purchase one-fortieth (1/40th) of a share of Class A Common Stock at an exercise price of $460.00 per share shares in Q3 2024.
  • Royal Bank of Canada first reported a position in Ginkgo Bioworks Holdings, Inc. Warrants, each whole warrant exercisable to purchase one-fortieth (1/40th) of a share of Class A Common Stock at an exercise price of $460.00 per share in Q3 2021 and held it in 12 quarters.
  • Royal Bank of Canada's Ginkgo Bioworks Holdings, Inc. Warrants, each whole warrant exercisable to purchase one-fortieth (1/40th) of a share of Class A Common Stock at an exercise price of $460.00 per share position peaked at $2K in Q3 2021.
  • 5 funds tracked by Wall St. Rank held Ginkgo Bioworks Holdings, Inc. Warrants, each whole warrant exercisable to purchase one-fortieth (1/40th) of a share of Class A Common Stock at an exercise price of $460.00 per share as of Q3 2024.

Based on Royal Bank of Canada's 13F filing for Q3 2024, filed 14 Nov 2024.